BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Syngene International extends long-term research collaboration with Bristol Myers Squibb until 2035

19 January 2026 | News

Expanded agreement broadens the scope of integrated services across the drug development lifecycle



Syngene International, a global contract research, development, and manufacturing organization (CRDMO), has announced the extension of its long-standing strategic collaboration with Bristol Myers Squibb through 2035.

The expanded agreement broadens the scope of integrated services across the drug development lifecycle spanning discovery (chemistry, biology, drug metabolism and pharmacokinetics), translational sciences, pharmaceutical development and manufacturing, clinical trials, data and information technology services to enable seamless progression from research to commercialisation.

The expansion of this collaboration marks the next phase of growth, reinforcing Syngene's position as a strategic partner delivering integrated, end-to-end scientific and manufacturing solutions.

The collaboration between Syngene and Bristol Myers Squibb began in 1998, culminating in the establishment of the Biocon Bristol Myers Squibb Research and Development Center (BBRC), Syngene's first dedicated R&D Center, which was fully commissioned in 2009.

Over the years, the BBRC
has evolved into a major strategic R&D site for Bristol Myers Squibb, supporting integrated capabilities across target identification, lead discovery, lead optimization, pharmaceutical development, molecular and cell biology, protein sciences, assay biology and clinical biomarkers.

The center, which today houses around 700 Syngene scientists working as an extension of Bristol Myers Squibb's global research organization, contributes to discovery, preclinical development, and patent filings across therapeutic areas including cardiovascular, fibrosis, immunology, and oncology.

Since its inception, BBRC has played a pivotal role in accelerating the progression of novel compounds from early discovery to first-in-human studies, thereby helping reduce development timelines and overall costs for Bristol Myers Squibb.